Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge?
Level V
Where this comes from
- Record sourced from PubMed, PMID 19247382.
- Also identified by DOI 10.1038/ki.2008.663.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Arterial calcification has been found to coexist with bone loss. Bisphosphonates, used as standard therapy for osteoporosis, inhibit experimentally induced vascular calcification, offering perspectives for the treatment of vascular calcification in renal failure patients. However, Lomashvili et al. report that the doses of etidronate and pamidronate that are effective in attenuating aortic calcification also decrease bone formation and mineralization in uremic rats, limiting their therapeutic use as anticalcifying agents.
Medical subject headings
- Calcification, Physiologic
- Calcinosis
- Diphosphonates